吉非替尼与托瑞米芬在肺癌治疗中的临床价值分析

Analysis of the clinical value of gefitinib and toremifen in the treatment of lung cancer

目的研究吉非替尼与托瑞米芬在肺癌治疗中的临床价值。方法选择2017年6月—2018年8月本院收治的120例肺癌患者作为研究对象,并采用电脑随机法将患者分为观察组和对照组两组,每组各60例。观察组实施吉非替尼治疗,对照组实施托瑞米芬治疗。分析两组治疗效果、肺癌进展和生存时间、免疫功能指标。结果观察组肺癌患者治疗总有效率(96.67%)高于对照组总有效率,差异有统计学意义(P<0.05)。观察组肺癌患者肺癌进展时间、肺癌生存时间较对照组更长,差异有统计学意义(P<0.05)。观察组肺癌患者免疫功能指标水平均高于对照组,差异有统计学意义(P<0.05)。结论吉非替尼与托瑞米芬相比较,前者在肺癌的治疗中更具有价值,同时能够使患者免疫功能得到改善,使其生存时间延长,值得进一步推广与研究。

Objective To study the clinical value of gifetinib and toremifen in the treatment of lung cancer.Methods The patients with lung cancer were selected as subjects in this study,and 120 patients with lung cancer were divided into observation group and control group"computer randomization"method.Patients in the observation group were treated with gifetinib,and patients in the control group were treated with toremifen.The therapeutic effect,progression and survival time of patients with lung cancer and immune function indexes of the patients were analyzed.Results The total effective rate of lung cancer in the observation group(96.67%)was higher than that in the control group(P<0.05).The progression time and survival time of patients with lung cancer in observation group was longer than those of control group(P<0.05).The level of immune function in patients with lung cancer in the observation group was higher than that in the control group(P<0.05).Conclusions Gefitinib is more valuable in the treatment of lung cancer than that of toremifen,and it could improve the immune function and prolong the survival time of patients.